Intuitive Surgical, Inc. — Fundamental Stock Analysis and Report Card
Located in Sunnyvale, CA, US. Intuitive Surgical, Inc. is a leading medical technology firm dedicated to advancing patient care by developing, producing, and commercializing sophisticated tools. These innovations empower medical professionals to deliver superior, accessible, and less-invasive treatment options to patients both within the United States and across international markets. Its flagship offering, the da Vinci Surgical System, facilitates intricate operations through a minimally disruptive approach. Expanding beyond surgical applications, the company also provides the Ion endoluminal system, designed for diagnostic interventions like minimally invasive lung biopsies. Complementing its primary systems, Intuitive Surgical supplies a comprehensive array of instruments, including stapling tools, energy devices, and essential core components. Furthermore, it offers structured training programs to ensure proficient use of its technology, alongside extensive customer support services encompassing installation, repairs, and ongoing maintenance. The firm also integrates digital capabilities to deliver unified, connected solutions that optimize hospital performance through actionable insights. Established in 1995, Intuitive Surgical maintains its corporate headquarters in Sunnyvale, California.
Revenue, earnings and profitability.
Strong revenue growth and earnings can attract investors, driving the stock price up. Profitability indicates the company's efficiency and sustainability, which impacts investor confidence. Poor performance in these areas can lead to a decrease in stock price.
Revenue History
Earnings History
Margins
Income & Cash Flow analysis.
An income statement shows what a company earned and spent over a period — revenue at the top, costs and expenses in between, and net income at the bottom. A cash flow statement tracks the actual cash moving in and out, across operations, investing, and financing. Read together, they show whether reported earnings are backed by real cash.
Q2 2026 Total ($) | Q2 2026 Margin (%) | |
|---|---|---|
| Revenue | 2.9b +452.3m +18.5% | |
| Gross Income | 2.0b +342.5m +21.2% | 68% +1.5pp +2.2% |
| EBITDA | 1.2b +186.9m +18.9% | 41% +0.1pp +0.3% |
| Operating Income | 971.9m +228.5m +30.7% | 34% +3.1pp +10.3% |
| Net Income | 818.1m +159.7m +24.3% | 28% +1.3pp +4.8% |
| Earnings Per Share | 2.32 +0.5 +26.1% | |
| Operating Cash Flow | 911.9m +330.3m +56.8% | 32% +7.7pp +32.3% |
| Free Cash Flow | 808.6m +343.6m +73.9% | 28% +8.9pp +46.7% |
| Research & Development | 370.6m +57.3m +18.3% | 13% +0.0pp -0.2% |
What are the analysts saying?
Analyst Consensus aggregates Wall Street recommendations into buy/hold/sell counts, while the Fundamental Scorecard grades the company on six financial ratios (P/B, P/E, D/E, ROA, ROE, DCF) plus an overall score. The two measure different things and can point in different directions.